<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J High Risk Behav Addict</journal-id><journal-id journal-id-type="iso-abbrev">Int J High Risk Behav Addict</journal-id><journal-id journal-id-type="doi">10.5812/ijhrba</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>International Journal of High Risk Behaviors &#x00026; Addiction</journal-title></journal-title-group><issn pub-type="ppub">2251-8711</issn><issn pub-type="epub">2251-872X</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27162761</article-id><article-id pub-id-type="pmc">4859933</article-id><article-id pub-id-type="doi">10.5812/ijhrba.24421</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The Effects of Family-Centered Problem-Solving Education on Relapse Rate, Self Efficacy and Self Esteem Among Substance Abusers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Habibi</surname><given-names>Rahim</given-names></name><xref ref-type="aff" rid="aff78504">1</xref></contrib><contrib contrib-type="author"><name><surname>Nikbakht Nasrabadi</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="aff78505">2</xref></contrib><contrib contrib-type="author"><name><surname>Shabany Hamedan</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff78506">3</xref><xref ref-type="corresp" rid="cor78507">*</xref></contrib><contrib contrib-type="author"><name><surname>Saleh Moqadam</surname><given-names>Amirreza</given-names></name><xref ref-type="aff" rid="aff78508">4</xref></contrib></contrib-group><aff id="aff78504"><label>1</label>Deputy Dean For International Affairs, Operating Room Department, Paramedical Faculty, Qazvin University of Medical Sciences, Qazvin, IR Iran</aff><aff id="aff78505"><label>2</label>Deputy Dean for International Affairs, Nursing and Midwifery Faculty, Tehran University of Medical Sciences, Tehran, IR Iran</aff><aff id="aff78506"><label>3</label>Brain and Spinal Cord Injuries Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, IR Iran</aff><aff id="aff78508"><label>4</label>Nursing Management and Mental Health Department, Nursing and Midwifery Faculty, Mashhad University of Medical Sciences, Mashhad, IR Iran</aff><author-notes><corresp id="cor78507"><label>*</label>Corresponding author: Maryam Shabany Hamedan, Brain and Spinal Cord Injuries Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, IR Iran. Tel: +98-2177361961, E-mail: <email>maryamshabanyi@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2016</year></pub-date><volume>5</volume><issue>1</issue><elocation-id>e24421</elocation-id><history><date date-type="received"><day>11</day><month>10</month><year>2014</year></date><date date-type="rev-recd"><day>01</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016, Zahedan University of Medical Sciences.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p><!--CREATIVE COMMONS-->This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>The success of drug abuse treatment and relapse prevention methods depends widely on not only pharmaceutical and non-pharmaceutical therapies but also self efficacy and self esteem promotion.</p></sec><sec><title>Objectives:</title><p>The current study attempted to clarify the effects of Problem Solving Education (PSE) on relapse rate, self efficacy and self esteem among drug abusers.</p></sec><sec><title>Patients and Methods:</title><p>This non-controlled clinical trial (quasi-experimental) assessed 60 opium and heroin abusers who were willing to quit and were referred to the Mehr Center of Addiction Treatment and Rehabilitation Facility. The patients were allocated to two groups of 30 (intervention and control groups). While both groups received the routine care of the clinic, the intervention group also attended eight 45-minute family-centered PSE sessions. The Coopersmith Self esteem Inventory and Quit Addiction Self efficacy Questionnaire were filled out for all subjects before and after the intervention. Drug relapse was investigated four times with two-week intervals. The two groups were compared using chi-square and Student&#x02019;s-t tests. Logistic regression analysis was applied to determine factors affecting drug relapse.</p></sec><sec><title>Results:</title><p>A total of 45 individuals (21 and 24 in the intervention and control groups, respectively) completed the study. At baseline, the two groups had no significant difference regarding their mean scores of self esteem and self efficacy (P = 0.692 and 0.329, respectively). After the intervention, however, the mean changes of self esteem scores were 20.10 &#x000b1; 3.75 for the intervention group and 4.50 for the control group (P &#x0003c; 0.001). The mean changes of self efficacy scores in the mentioned groups were 34 34.17 &#x000b1; 5.19 and 9.03&#x000b1; 2.04, respectively (P &#x0003c; 0.001). Drug relapse after two weeks was correlated with age (OR = 1.216; P = 0.026; 95% CI: 1.024-1.445) and implementation of the intervention (OR = 0.036; P = 0.003; 95% CI: 0.004-0.322).</p></sec><sec><title>Conclusions:</title><p>According to our findings, supplementing drug abuse treatment with cognitive behavior therapy, particularly PSE, can reduce relapse rate and enhance self efficacy and self esteem among patients.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Drug Users</kwd><kwd>Problem Solving</kwd><kwd>Self Efficacy</kwd><kwd>Self Esteem</kwd></kwd-group></article-meta></front><body><sec id="sec142154"><title>1. Background</title><p>Substance abuse is a fundamental economic and health problem in the world, which exerts a variety of physical, psychological, and social impacts on both the person with addiction and the community (<xref rid="A24421R1" ref-type="bibr">1</xref>). Use of opioids has an annual prevalence of 0.3% to 0.5% among the adult population (<xref rid="A24421R2" ref-type="bibr">2</xref>).</p><p>The numerous physical complications of substance abuse include infectious diseases such as Acquired Immune Deficiency Syndrome (AIDS) and hepatitis C, liver and gastrointestinal diseases, cancers (<xref rid="A24421R3" ref-type="bibr">3</xref>-<xref rid="A24421R5" ref-type="bibr">5</xref>), osteoporosis (<xref rid="A24421R6" ref-type="bibr">6</xref>), ischemic heart diseases (<xref rid="A24421R7" ref-type="bibr">7</xref>), and even death (<xref rid="A24421R7" ref-type="bibr">7</xref>, <xref rid="A24421R8" ref-type="bibr">8</xref>). On the other hand, increased stress, anxiety, depression, psychosis, loss of control and the power to decide, and decreased self efficacy are among the psychological side effects of the habit (<xref rid="A24421R9" ref-type="bibr">9</xref>, <xref rid="A24421R10" ref-type="bibr">10</xref>). </p><p>Considering the above-mentioned complications, pharmaceutical treatments with methadone, buprenorphine and naltrexone, and non-pharmaceutical treatments have been suggested to treat this problem (<xref rid="A24421R11" ref-type="bibr">11</xref>). However, research has shown a high relapse rate following withdrawal (<xref rid="A24421R12" ref-type="bibr">12</xref>). </p><p>A number of physical, psychological and personality characteristics, such as self efficacy, can influence drug relapse (<xref rid="A24421R13" ref-type="bibr">13</xref>). Bandura defined self efficacy as one&#x02019;s belief in his/her ability to plan and take appropriate steps to succeed in achieving a better situation (<xref rid="A24421R13" ref-type="bibr">13</xref>). Self esteem is another crucial factor in drug abuse treatment and commitment to treatment. It provokes feelings of confidence and independence. High self esteem is associated with greater problem-solving skills and higher ability to analyze problematic situations (<xref rid="A24421R14" ref-type="bibr">14</xref>-<xref rid="A24421R18" ref-type="bibr">18</xref>). </p><p>The highest rate of opioids abuse, particularly opium and heroin, has been reported in Iran (<xref rid="A24421R19" ref-type="bibr">19</xref>). Researchers have estimated the prevalence of opium abuse in the country at 1.8% to 9.0% (<xref rid="A24421R20" ref-type="bibr">20</xref>-<xref rid="A24421R22" ref-type="bibr">22</xref>). Despite the application of various treatment methods, drug relapse is still common in Iran (<xref rid="A24421R23" ref-type="bibr">23</xref>). Therefore, designing strategies to prevent drug relapse in abusers, who have been successfully treated, seems essential. Behavioral therapy techniques, such as problem-solving education, are training methods focusing on improving skills and problem-solving attitudes (<xref rid="A24421R16" ref-type="bibr">16</xref>, <xref rid="A24421R17" ref-type="bibr">17</xref>). On the other hand, family as a center for problem solving may be effective for adolescent behavioral problems in drug abusers within diverse populations, and it may be better than nonfamily alternatives (<xref rid="A24421R24" ref-type="bibr">24</xref>). </p><p>Since self esteem and self efficacy can substantially decrease drug relapse, their promotion can be respected as a supportive strategy during drug abuse treatment. Also, health care providers, such as nurses, can guide and support the family in solving their problems, and provide practical care services, and induce a sense of acceptance by careful listening to concerns and suggestions of other family members (<xref rid="A24421R22" ref-type="bibr">22</xref>). Furthermore, learning and application of problem solving skills is deeply felt in all nursing roles, especially in education and managerial roles, thus nurses can use the results of this study effectively (<xref rid="A24421R15" ref-type="bibr">15</xref>).</p></sec><sec id="sec142155"><title>2. Objectives</title><p>The current study sought to evaluate the effects of family-centered problem-solving education on slip (relapse) rate and levels of self efficacy and self esteem among drug abusers.</p></sec><sec id="sec142157"><title>3. Patients and Methods</title><p>In this clinical trial, convenience sampling was applied to select the participants from all drug abusers who visited the Mehr center of addiction treatment and rehabilitation facility (Mashhad, Iran), during spring and winter 2012. Sampling lasted for six months; forty people were selected in winter and 20 people in spring. There was no gap in time and sampling depended on number of referred addicts in clinic. Furthermore, the intervention program lasted for two months. Individuals were included only if they had a non-addict, literate family member who agreed to participate in the study and problem-solving sessions, were Iranian citizens, had lived in Mashhad for at least five years, aged between 16 and 40 years old, and could read and write. Addiction was confirmed by the facility&#x02019;s physician based on patient records. Other inclusion criteria were heroin or opium abuse, history of addiction less than ten years, not having experienced more than two relapses, absence of drug dependence, and not having attended a formal training course on addiction. Finally, the participants (either the patients or their family members) could not be health personnel. </p><p>During the course of the study, subjects who developed psychological disorders, chronic and progressive diseases such as cancer and diabetes, and infectious diseases like AIDS and hepatitis, according to the facility&#x02019;s specialists, were excluded. The intervention group members who failed to participate in training classes or more than one problem-solving education session were also excluded. Besides, unwillingness of the participants and/or their family members to continue the treatment program led to their exclusion. </p><p>Based on similar clinical trials, the sample size was calculated using the difference in means formula and considering the maximum number of subjects and self efficacy as the dependent variable.</p><disp-formula id="EQ4485"><mml:math id="MML4485"><mml:mstyle displaystyle="true"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>(</mml:mi><mml:msubsup><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mi>)</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>(</mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi>)</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><p>With Confidence Interval (CI) and test power equal to 95% (&#x003b1; = 5%) and 80% (&#x003b2; = 20%), respectively, the sample size was determined as 30. The selected subjects were then allocated to either intervention or control group using coin flips. </p><p>At the beginning of the study, the participants were asked to provide written informed consent and introduced an eligible family member with whom they felt more comfortable. A questionnaire containing demographic characteristics, the Coopersmith Self Esteem Inventory (CSEI), and Quit Addiction Self Efficacy Questionnaire (QASEQ) were filled out for all subjects at baseline. The latter is a 16-item questionnaire designed by Bramson to assess self efficacy in drug dependent patients. It measures problem solving, decision-making, self-expression, and relationship skills using questions scored based on a seven-point Likert scale (with scores one to seven for definitely no, probably no, perhaps no, no idea, perhaps yes, probably yes, definitely yes, respectively) resulting in a total score of 16 to 112. The validity of the QASEQ was confirmed by Martin (1995) and Bramson (1999) Face and content validity of the Farsi version of the QASEQ was also evaluated by Habibi et al. who reported the correlation between QASEQ and the General Self Efficacy Questionnaire (a validated questionnaire in Iran) as r = 0.6 (P &#x0003c; 0.001)(<xref rid="A24421R25" ref-type="bibr">25</xref>). The reliability of the tool was also approved by a Cronbach&#x02019;s alpha value of 0.90 (<xref rid="A24421R25" ref-type="bibr">25</xref>). </p><p>The CSEI was developed and utilized by Coopersmith to gauge general self esteem (<xref rid="A24421R26" ref-type="bibr">26</xref>-<xref rid="A24421R28" ref-type="bibr">28</xref>). It consists of 35 items on a four-point Likert scale (1: strongly agree; 2: agree; 3: disagree; 4: strongly disagree), which yield a total score of 35-140. We categorized self esteem as low, moderate and high (scores: 35-70, 71-105, and 106-140, respectively) in the present study. Moreover, in order to examine the reliability of the questionnaire, it was distributed among 20 drug addicts and completed again by the same population after ten days (test-retest method). Finally, a reliability coefficient of r = 0.85 suggested the CSEI to be acceptably reliable.</p><p>The intervention was initiated after the questionnaires had been completed. Both groups received routine care, including weekly meetings with the physician and a minimum of biweekly psychological counseling and social work services, at the facility for two months. The intervention group and their family members also participated in a problem-solving education course, which comprised of eight 45-minute weekly sessions and covered physical, psychological and social-family problems. The education started with sessions to pose the question and continued with data collection, hypotheses formulation and testing, conclusion, and final evaluation, which are the five steps of problem solving-education. In order for the families to reach solutions faster, they were presented with previously prepared handouts. Eight sessions were held and in the first session, the researcher explained the study objectives, and became familiar with families and their points of view. Next, families were divided to three groups of ten for participation in future group discussions.</p><p> In the second session, the researcher defined the terms addiction and addict, variety of addictions, causes and roots, common treatments, and problem solving training method in simple words for the study subjects in each group. In this session, problems were identified and classified in three areas of physical, mental, and social-family. The effected family member had to collect information about solutions to the problems, by studying educational notes and using other sources such as radio, TV, the internet, books, etc. </p><p>In the third session, study subjects were encouraged to suggest the best and most suitable solutions for the problems of the patients in the physical area, thus they listed the problems faced by their patient.</p><p>In the fourth session, study subjects were asked to describe the best and most suitable solutions for their patients&#x02019; problems. By the end of the fourth session, the researcher pursued progress of the effected family members in solving physical problems of the patients.</p><p>In the fifth session, study subjects were asked to describe the best and most suitable solutions they could think of for their patients&#x02019; psychological problems. At the end of the fifth session, the researcher followed up the status of solutions of patient&#x02019;s psychological problems by the effected family member.</p><p>In the sixth session, in addition to following up progress of solving patient&#x02019;s social-family problems by the effected family member, the researcher also pursued implemented solutions and all the steps taken by this stage, answered the questions raised by the families with assistance of the psychiatrist, social worker and clinic&#x02019;s psychologist. </p><p>In the seventh session, a meeting was held with participation of drug-dependent patients and patients could be familiarized with problem solving techniques and how they should cooperate with their families. </p><p>In the eighth and final session, the researcher with cooperation of families, social worker and clinic&#x02019;s psychologist and using group discussions, followed up patients&#x02019; comments from previous sessions, and answered their questions.</p><p>Generally, during each session, patients and their family members brainstormed patient problems and various solutions were proposed by patients, families, the researcher, and the facility&#x02019;s psychologist and social worker. In the meantime, the researcher responded to the participants&#x02019; questions via direct contact during training sessions and regular phone calls throughout the course of the study.</p><p>Once problem-solving education was complete, both groups filled out the QASEQ and CSEI for a second time. In both groups, drug relapse (slip) was assessed using a morphine test device (ACON, USA), every two weeks, and the results were recorded. The test is commonly implemented as a valid tool in addiction treatment clinics in Iran. The reliability and validity of this particular kit have been previously confirmed, using the test-retest method (r = 0.91) by Habibi et al. (<xref rid="A24421R25" ref-type="bibr">25</xref>). </p><p>The collected data was analyzed with the SPSS software for Windows 20.0 (SPSS Inc., Chicago, IL, USA). Paired t-tests were applied to determine intergroup differences between the scores before and after the intervention. Intergroup comparisons between the mean changes of the scores and the frequency of drug relapse were made using Student&#x02019;s t-test and both chi-square and Fisher&#x02019;s exact tests, respectively. Logistic regression analysis was performed to identify possible factors affecting relapse, e.g. demographic characteristics (age, gender, marital status, income and education level), the relationship between the patient and his/her family member, type of abused drug, duration of addiction, implementation of the intervention, and mean changes of self efficacy and self esteem scores. Analysis of Covariance (ANCOVA) was carried out to determine factors affecting self esteem and self efficacy scores after the intervention. Also, repeated measure ANOVA analysis was used to evaluate scores within and between groups. Again, the mentioned demographic characteristics, the relationship between the patient and his/her family member, type of abused drug, duration of addiction, implementation of the intervention, and baseline scores of self esteem and self efficacy were included.</p><sec id="sec142156"><title>3.1. Ethics Committee Approval and Monitoring</title><p>This research was completed as part of a graduate student project, code 89392 and under the Research Council of Mashhad University of Medical Sciences and the University Ethics Committee approved the study) number 3142/511 dated Sunday, January 16th, 2011) (10.26.1389 in Shamsi).</p></sec></sec><sec id="sec142158"><title>4. Results</title><p>The present study evaluated 60 individuals in two groups of 30 (i.e. intervention and control). Twenty-one patients from the intervention group and 24 patients from the control group completed the study and underwent all relapse tests. The mean age of patients was 34.27 &#x000b1; 3.30 years (range: 21-40 years). The intervention and control groups were matched in terms of mean age. <xref ref-type="table" rid="tbl36516">Table 1</xref> shows baseline characteristic information of patients included in this study.</p><table-wrap id="tbl36516" orientation="portrait" position="float"><label>Table 1.</label><caption><title> Comparison of Demographic Characteristics and Drug Abuse-Related Information of the Two Groups at Baseline</title></caption><table frame="hsides" rules="groups"><thead><tr><th style="vertical-align: top;text-align: left;" rowspan="1" colspan="1">Variable</th><th style="vertical-align: top;" rowspan="1" colspan="1">Control Group (n = 30) <sup><xref ref-type="table-fn" rid="fn39010">a</xref></sup></th><th style="vertical-align: top;" rowspan="1" colspan="1">Intervention Group (n = 30) <sup><xref ref-type="table-fn" rid="fn39010">a</xref></sup></th><th style="vertical-align: top;" rowspan="1" colspan="1">P Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Age, y</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">34.33 &#x000b1; 5.88</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">34.20 &#x000b1; 5.60</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.929</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Family member</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Age</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">31.43 &#x000b1; 5.59</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">31.47 &#x000b1; 6.30</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.983</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Relationship (spouse)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">26 (86.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">22 (73.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.197</td></tr><tr><td rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">1.000</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Male</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">28 (93.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">28 (93.3)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Female</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">2 (6.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">2 (6.7)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Reason for quitting</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.936</td></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Patient&#x02019;s will</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">11 (36.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">9 (30.0)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Family issues</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">7 (23.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">7 (23.3)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Cost of drugs</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">5 (16.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">8 (26.7)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Work issues</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">3 (10.0)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">3 (10.0)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Physical and mental issues</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">4 (13.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">3 (10.0)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Marital status (married)</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">26 (86.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">24 (80.0)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.488</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Education level (high school and more)</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">8 (26.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">7 (23.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.766</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Income (adequate)</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">11 (36.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">15 (50.0)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.297</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Employed</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">23 (76.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">21 (70.0)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.960</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Owning a house</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">16 (53.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">12 (40)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.301</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Type of drug abuse</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.569</td></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Injection</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">2 (6.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">2 (6.7)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Inhalation</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">16 (53.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">12 (40.0)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Oral</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">12 (40.0)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">16 (53.3)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>History of drug abuse (years)</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">5.13 &#x000b1; 2.66</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">5.00 &#x000b1; 2.56</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.844</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Smoking more than 10 cigarettes a day</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">16 (53.4)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">17 (56.6)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.925</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Having an addict family member</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">10 (33.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">9 (30.0)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.781</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Type of drug</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.438</td></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Opium</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">17 (56.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">14 (46.7)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Heroin</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">13 (43.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">16 (53.3)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Monthly cost of drugs (10000 Rials)</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">20.65 &#x000b1; 13.65</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">19.42 &#x000b1; 12.30</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.714</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Drug usage (g/month)</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">7.77 &#x000b1; 3.78</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">8.00 &#x000b1; 4.27</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.823</td></tr></tbody></table><table-wrap-foot><fn id="fn39010"><p><sup>a</sup>Data are presented as mean &#x000b1; SD and No. (%).</p></fn></table-wrap-foot></table-wrap><p><xref ref-type="table" rid="tbl36517">Table 2</xref> compares the scores of the two groups in terms of self efficacy and self esteem scores before and after the intervention.</p><table-wrap id="tbl36517" orientation="portrait" position="float"><label>Table 2.</label><caption><title> Mean Scores of Self Efficacy and Self Esteem Before, After and During Follow up</title></caption><table frame="hsides" rules="groups"><thead><tr><th style="vertical-align: middle;" rowspan="1" colspan="1"/><th style="vertical-align: top;" rowspan="1" colspan="1">Before</th><th style="vertical-align: top;" rowspan="1" colspan="1">After</th><th style="vertical-align: top;" rowspan="1" colspan="1">Follow Up</th><th style="vertical-align: top;" rowspan="1" colspan="1">P Value (Test Within
Subjects)</th><th style="vertical-align: top;" rowspan="1" colspan="1">P Value (Test Between
Subjects)</th></tr></thead><tbody><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Self esteem</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">0.041</td></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Intervention</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">88.57 &#x000b1; 21.20</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">108.67 &#x000b1; 19.49</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">117.53 &#x000b1; 9.08</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.001</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Control</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">90.80 &#x000b1; 22.18</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">95.30 &#x000b1; 22.43</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">95.63 &#x000b1; 22.75</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.001</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Self efficacy</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Intervention</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">61.13 &#x000b1; 8.53</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">95.30 &#x000b1; 9.08</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">104.03 &#x000b1; 7.06</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.001</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Control</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">63.33 &#x000b1; 8.79</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">72.37 &#x000b1; 9.35</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">74.30 &#x000b1; 9.84</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.001</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>According to <xref ref-type="table" rid="tbl36517">Table 2</xref>, the mean scores of self efficacy and self esteem of both groups increased significantly after the intervention. Also, repeated measure Analysis of Variance (ANOVA) to evaluate within and between groups was done. It showed significant differences within groups (during the time) and between groups for both self esteem and self efficacy.</p><p>The mean changes of self efficacy and self esteem scores along with the frequency of relapse are presented in <xref ref-type="table" rid="tbl36518">Table 3</xref>.</p><table-wrap id="tbl36518" orientation="portrait" position="float"><label>Table 3.</label><caption><title> Mean Changes of Self Efficacy and Self Esteem Scores and Frequency of Relapse at Specific Intervals for the Intervention and Control Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th style="vertical-align: middle;" rowspan="1" colspan="1"/><th style="vertical-align: middle;" rowspan="1" colspan="1">Control Group</th><th style="vertical-align: middle;" rowspan="1" colspan="1">Intervention Group</th><th style="vertical-align: middle;" rowspan="1" colspan="1">P Value</th></tr></thead><tbody><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Self esteem score</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">95.30 &#x000b1; 22.43</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">108.67 &#x000b1; 19.49</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.017</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Changes in self esteem score</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">4.50</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">20.10 &#x000b1; 3.75</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Self efficacy score</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">72.37 &#x000b1; 9.35</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">95.30 &#x000b1; 9.08</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Changes in self efficacy score</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">9.03 &#x000b1; 2.04</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">34.17 &#x000b1; 5.19</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Drug relapse, No (%)</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Second week</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">9 (30.0)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">4 (13.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.117</td></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Fourth week</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">9 (30.0)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">3 (10)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.053</td></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Sixth week</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">12 (40.0)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">2 (6.7)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.002</td></tr><tr><td style="padding-left: 20pt;vertical-align: middle;" rowspan="1" colspan="1">Eighth week</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">13 (43.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">1 (3.3)</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr></tbody></table></table-wrap><p>The mean changes of self efficacy and self esteem scores were significantly higher in the intervention group than in the control group. Moreover, compared to the intervention group, the control group had significantly greater frequency of relapse two, six and eight weeks after baseline. On the whole, the frequency of relapse reduced in the intervention group and increased in the control group with passing time. </p><p>The ANCOVA results revealed that implementation of the intervention, baseline self esteem score, monthly income, and type of abused drug had significant relationships with increased self esteem score at the end of the study. On the other hand, implementation of the intervention and baseline self efficacy scores had significant effects on the final self efficacy scores.</p><p>Logistic regression analysis suggested the relapse on the eighth week to be significantly correlated with age (odds ratio: 1.216; 95% CI: 1.024-1.445; P = 0.026) and implementation of the intervention (odds ratio: 0.036; 95% CI: 0.004-0.322; P = 0.003).</p></sec><sec id="sec142159"><title>5. Discussion</title><p>The present study indicated that problem-solving education in presence of a family member (as the supporter) significantly promotes self efficacy and self esteem among drug abusers throughout the process of quitting. Furthermore, the frequency of relapse was significantly higher in the control group than in the intervention group. Hogue et al. in their study found that family therapy may be effective for adolescent behavior problems in drug abusers within diverse populations, and it may be better than nonfamily alternatives (<xref rid="A24421R24" ref-type="bibr">24</xref>). </p><p>Opioids abuse treatment programs may be categorized as pharmaceutical treatments with methadone, buprenorphine and naltrexone, and non-pharmaceutical treatments including counseling and behavioral therapies (<xref rid="A24421R11" ref-type="bibr">11</xref>).</p><p>Despite the presence of comprehensive plans, drug relapse has been reported in various studies. Dunn et al. in a review of 28 studies on relapse rate following addiction treatment with buprenorphine, found that the median frequency of individuals who stayed serious in quitting addiction during the follow-up period was 23%. Interestingly, in five studies, only 30% of the participants had continued abstinence from drugs until the last day of treatment (<xref rid="A24421R29" ref-type="bibr">29</xref>). </p><p>Drug relapse might occur as a result of several factors including the stressful nature of withdrawal, properties of prescribed medicines and external factors such as stressors (<xref rid="A24421R30" ref-type="bibr">30</xref>). Inadequate treatment due to lack of medical personnel and facilities, counseling, occupational therapy, and post-treatment education in addiction treatment centers can also be responsible for drug relapse (<xref rid="A24421R31" ref-type="bibr">31</xref>). On the other hand, different treatment modalities, especially with methadone, have to be accompanied by behavioral treatment. Research has in fact shown the absence of the latter to increase the frequency of relapse (<xref rid="A24421R32" ref-type="bibr">32</xref>). </p><p>The frequency of drug relapse has also been evaluated in Iran. Shirinbayan et al. examined the frequency of sobriety for seven methadone treatment centers in four cities of Iran and concluded that 17.7% had resumed abuse simultaneous with treatment. Long distance to the clinic, absence of family and social support, and lack of determination were introduced as factors affecting relapse rate (<xref rid="A24421R33" ref-type="bibr">33</xref>).</p><p>Marlatt and Donovan proposed Cognitive-Behavioral Treatment (CBT) as an efficient way to reduce relapse rate (<xref rid="A24421R34" ref-type="bibr">34</xref>). Problem-solving education, performed in the current research, is a CBT method where individuals become actively involved in discussing and solving their own problems as well as the others (<xref rid="A24421R35" ref-type="bibr">35</xref>). Our findings highlighted the significant difference in relapse rate between the intervention and control groups. The intervention group compared with the control group had higher scores in self efficacy and self esteem. Nevertheless, logistic regression analysis asserted the implementation of intervention and younger age as the only preventive factors of relapse.</p><p>A remarkable finding of the present research was the increased mean self efficacy and self esteem scores as a consequence of the intervention. As self efficacy is a major component of success, and reflects one&#x02019;s belief in one&#x02019;s ability to perform tasks (<xref rid="A24421R36" ref-type="bibr">36</xref>), its enhancement may reduce drug relapse. Miller et al. reviewed ten studies on self efficacy promotion and behavior modification among cigarette smokers and alcohol and drug abusers. They observed increased self efficacy in only six studies out of which two had reported behavioral changes regarding addiction. While none of the mentioned studies had assessed the direct effects of increased self efficacy on addiction management and treatment, Miller et al. hypothesized that self efficacy might cause behavioral improvements in addicts (<xref rid="A24421R37" ref-type="bibr">37</xref>).</p><p>Another noteworthy result of the current study was the gradual reduction in frequency of relapse. The substantial intergroup difference in relapse rate (3.3% in the intervention group vs. 43.3% in the control group) despite similar baseline characteristics, pharmaceutical treatment and counseling, contends the efficacy of CBT, i.e. problem-solving education in the presence of a supportive family member. The benefits of CBT have also been demonstrated in previous studies. Pashaei et al. analyzed the effectiveness of methadone treatment alone and in combination with CBT and suggested the second to lead to considerably lower relapse rates (<xref rid="A24421R38" ref-type="bibr">38</xref>). </p><p>According to the result, it is suggested for policy makers to conduct education courses about family and addiction for physicians and health workers of addiction treatment centers. It is suggested for physicians and health workers to take part in these courses. </p><p>Findings of the present study highlighted the significant effects of problem-solving education on improving self efficacy and self esteem scores and reducing relapse during the course of treatment. Supplementing addiction treatment modalities with CBT is thus recommended. Besides, further studies to compare various CBT methods, including problem-solving education, are indispensable for designing more successful interventions in the future.</p></sec></body><back><ack><p>The researchers are grateful to Dr. Latifnejad (Research Deputy of Mashhad Nursing and Midwifery School), Dr. Afsari (psychiatrist, chief of Mehr Addiction Treatment and Rehabilitation Facility), Ms. Monfared (social work expert), Ms. Hakimi (psychologist) and all other personnel and patients of Mehr Addiction Treatment and Rehabilitation Facility.</p></ack><fn-group><fn id="afn45767" fn-type="other"><p><bold>Authors&#x02019; Contribution:</bold>Study concept and design: Rahim Habibi; acquisition of data: Rahim Habibi; analysis and interpretation of data: Rahim Habibi and Maryam Shabany; drafting of the manuscript: Maryam Shabany; critical revision of the manuscript for important intellectual content: Maryam Shabany; statistical analysis: Rahim Habibi and Professor Nikbakht; administrative, technical, and material support: Rahim Habibi; study supervision: Amirreza saleh moqadam.</p></fn><fn id="afn45768" fn-type="other"><p><bold>Funding and Support:</bold>Mr. Habibi reported that he had received a research grant from The Mashhad University of Medical Science and he refunded the money to the university.</p></fn></fn-group><ref-list><title>References</title><ref id="A24421R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>KM</given-names></name></person-group><article-title>Health consequences of illegal drug use.</article-title><source>Curr Opin Psychiatry.</source><year>2009</year><volume>22</volume><issue>3</issue><fpage>287</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">19378381</pub-id></element-citation></ref><ref id="A24421R2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>UNODC.</collab></person-group><source>World Drug Report 2012</source><year>2012</year><publisher-loc>Vienna</publisher-loc><publisher-name>United Nations publication</publisher-name></element-citation></ref><ref id="A24421R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aliasgari</surname><given-names>MA</given-names></name><name><surname>Kaviani</surname><given-names>A</given-names></name><name><surname>Gachkar</surname><given-names>L</given-names></name><name><surname>Hosseini-Nassab</surname><given-names>SR</given-names></name></person-group><article-title>Is bladder cancer more common among opium addicts?</article-title><source>Urol J.</source><year>2004</year><volume>1</volume><issue>4</issue><fpage>253</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17914701</pub-id></element-citation></ref><ref id="A24421R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghadirian</surname><given-names>P</given-names></name><name><surname>Stein</surname><given-names>GF</given-names></name><name><surname>Gorodetzky</surname><given-names>C</given-names></name><name><surname>Roberfroid</surname><given-names>MB</given-names></name><name><surname>Mahon</surname><given-names>GA</given-names></name><name><surname>Bartsch</surname><given-names>H</given-names></name><etal>et al.</etal></person-group><article-title>Oesophageal cancer studies in the Caspian littoral of Iran: some residual results, including opium use as a risk factor.</article-title><source>Int J Cancer.</source><year>1985</year><volume>35</volume><issue>5</issue><fpage>593</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3997280</pub-id></element-citation></ref><ref id="A24421R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousavi</surname><given-names>MR</given-names></name><name><surname>Damghani</surname><given-names>MA</given-names></name><name><surname>Haghdoust</surname><given-names>AA</given-names></name><name><surname>Khamesipour</surname><given-names>A</given-names></name></person-group><article-title>Opium and risk of laryngeal cancer.</article-title><source>Laryngoscope.</source><year>2003</year><volume>113</volume><issue>11</issue><fpage>1939</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">14603052</pub-id></element-citation></ref><ref id="A24421R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gozashti</surname><given-names>MH</given-names></name><name><surname>Shahesmaeili</surname><given-names>A</given-names></name><name><surname>Amini Zadeh</surname><given-names>N</given-names></name></person-group><article-title>Is opium addiction a risk factor for bone loss?</article-title><source>Iran Red Crescent Med J.</source><year>2011</year><volume>13</volume><issue>7</issue><fpage>464</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22737513</pub-id></element-citation></ref><ref id="A24421R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosoosi Niaki</surname><given-names>MR</given-names></name><name><surname>Hamid</surname><given-names>M</given-names></name><name><surname>Farshidi</surname><given-names>F</given-names></name><name><surname>Mohammadpour</surname><given-names>M</given-names></name><name><surname>Salehi Omran</surname><given-names>MT</given-names></name></person-group><article-title>Evaluation of the role of opium addiction in acute myocardial infarction as a risk factor.</article-title><source>Caspian J Intern Med.</source><year>2013</year><volume>4</volume><issue>1</issue><fpage>585</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24009941</pub-id></element-citation></ref><ref id="A24421R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khademi</surname><given-names>H</given-names></name><name><surname>Malekzadeh</surname><given-names>R</given-names></name><name><surname>Pourshams</surname><given-names>A</given-names></name><name><surname>Jafari</surname><given-names>E</given-names></name><name><surname>Salahi</surname><given-names>R</given-names></name><name><surname>Semnani</surname><given-names>S</given-names></name><etal>et al.</etal></person-group><article-title>Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran.</article-title><source>BMJ.</source><year>2012</year><volume>344</volume><elocation-id>e24421</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.e2502</pub-id><pub-id pub-id-type="pmid">22511302</pub-id></element-citation></ref><ref id="A24421R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preston</surname><given-names>KL</given-names></name><name><surname>Epstein</surname><given-names>DH</given-names></name></person-group><article-title>Stress in the daily lives of cocaine and heroin users: relationship to mood, craving, relapse triggers, and cocaine use.</article-title><source>Psychopharmacology (Berl).</source><year>2011</year><volume>218</volume><issue>1</issue><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2183-x</pub-id><pub-id pub-id-type="pmid">21336579</pub-id></element-citation></ref><ref id="A24421R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teesson</surname><given-names>M</given-names></name><name><surname>Havard</surname><given-names>A</given-names></name><name><surname>Fairbairn</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Lynskey</surname><given-names>M</given-names></name><name><surname>Darke</surname><given-names>S</given-names></name></person-group><article-title>Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking.</article-title><source>Drug Alcohol Depend.</source><year>2005</year><volume>78</volume><issue>3</issue><fpage>309</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2004.12.001</pub-id><pub-id pub-id-type="pmid">15893162</pub-id></element-citation></ref><ref id="A24421R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>American Psychiatric Association Practice</surname><given-names>G</given-names></name></person-group><article-title>Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association.</article-title><source>Am J Psychiatry.</source><year>2001</year><volume>158</volume><issue>10 Suppl</issue><fpage>1</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11665545</pub-id></element-citation></ref><ref id="A24421R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adi</surname><given-names>Y</given-names></name><name><surname>Juarez-Garcia</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Jowett</surname><given-names>S</given-names></name><name><surname>Frew</surname><given-names>E</given-names></name><name><surname>Day</surname><given-names>E</given-names></name><etal>et al.</etal></person-group><article-title>Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.</article-title><source>Health Technol Assess.</source><year>2007</year><volume>11</volume><issue>6</issue><fpage>iii</fpage><lpage>v</lpage><pub-id pub-id-type="pmid">17280624</pub-id></element-citation></ref><ref id="A24421R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandura</surname><given-names>A</given-names></name></person-group><article-title>Self efficacy: toward a unifying theory of behavioral change.</article-title><source>Psychol Rev.</source><year>1977</year><volume>84</volume><issue>2</issue><fpage>191</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">847061</pub-id></element-citation></ref><ref id="A24421R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumeister</surname><given-names>RF</given-names></name><name><surname>Smart</surname><given-names>L</given-names></name><name><surname>Boden</surname><given-names>JM</given-names></name></person-group><article-title>Relation of threatened egotism to violence and aggression: the dark side of high self esteem.</article-title><source>Psychol Rev.</source><year>1996</year><volume>103</volume><issue>1</issue><fpage>5</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8650299</pub-id></element-citation></ref><ref id="A24421R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushman</surname><given-names>BJ</given-names></name><name><surname>Baumeister</surname><given-names>RF</given-names></name></person-group><article-title>Threatened egotism, narcissism, self esteem, and direct and displaced aggression: does self-love or self-hate lead to violence?</article-title><source>J Pers Soc Psychol.</source><year>1998</year><volume>75</volume><issue>1</issue><fpage>219</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">9686460</pub-id></element-citation></ref><ref id="A24421R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushman</surname><given-names>BJ</given-names></name><name><surname>Baumeister</surname><given-names>RF</given-names></name><name><surname>Thomaes</surname><given-names>S</given-names></name><name><surname>Ryu</surname><given-names>E</given-names></name><name><surname>Begeer</surname><given-names>S</given-names></name><name><surname>West</surname><given-names>SG</given-names></name></person-group><article-title>Looking again, and harder, for a link between low self esteem and aggression.</article-title><source>J Pers.</source><year>2009</year><volume>77</volume><issue>2</issue><fpage>427</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1111/j.1467-6494.2008.00553.x</pub-id><pub-id pub-id-type="pmid">19192074</pub-id></element-citation></ref><ref id="A24421R17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Maslow</surname><given-names>AH</given-names></name></person-group><source>Motivation and personality.</source><year>1981</year><publisher-name>Harper &#x00026; Row</publisher-name></element-citation></ref><ref id="A24421R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassanian-Moghaddam</surname><given-names>H</given-names></name><name><surname>Afzali</surname><given-names>S</given-names></name><name><surname>Pooya</surname><given-names>A</given-names></name></person-group><article-title>Withdrawal syndrome caused by naltrexone in opioid abusers.</article-title><source>Hum Exp Toxicol.</source><year>2014</year><volume>33</volume><issue>6</issue><fpage>561</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1177/0960327112450901</pub-id><pub-id pub-id-type="pmid">23690227</pub-id></element-citation></ref><ref id="A24421R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masoumi</surname><given-names>M</given-names></name><name><surname>Shahesmaeili</surname><given-names>A</given-names></name><name><surname>Mirzazadeh</surname><given-names>A</given-names></name><name><surname>Tavakoli</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>AZ</given-names></name></person-group><article-title>Opium addiction and severity of coronary artery disease: a case-control study.</article-title><source>J Res Med Sci.</source><year>2010</year><volume>15</volume><issue>1</issue><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">21526055</pub-id></element-citation></ref><ref id="A24421R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadi</surname><given-names>J</given-names></name><name><surname>Naghshvarian</surname><given-names>M</given-names></name><name><surname>Afshari</surname><given-names>R</given-names></name></person-group><article-title>Opioids use in male population referred for mandatory urine opioid screen before marriage in shiraz-iran.</article-title><source>Iran J Psychiatry Behav Sci.</source><year>2011</year><volume>5</volume><issue>2</issue><fpage>126</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">24644457</pub-id></element-citation></ref><ref id="A24421R21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>UNODC.</collab></person-group><source>World Drug Report 2009</source><year>2009</year><publisher-loc>Vienna</publisher-loc><publisher-name>United Nations Publications</publisher-name></element-citation></ref><ref id="A24421R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mokri</surname><given-names>A</given-names></name></person-group><article-title>Brief overview of the status of drug abuse in Iran.</article-title><source>Arch Iranian Med.</source><year>2002</year><volume>5</volume><issue>3</issue><fpage>184</fpage><lpage>90</lpage></element-citation></ref><ref id="A24421R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najafi</surname><given-names>K</given-names></name><name><surname>Amir Alavi</surname><given-names>C</given-names></name><name><surname>Zarrabi</surname><given-names>H</given-names></name><name><surname>Mohammadzadeh</surname><given-names>A</given-names></name><name><surname>Khodaei</surname><given-names>E</given-names></name><name><surname>Salajegeh</surname><given-names>A</given-names></name></person-group><article-title>Survey the Prevalence of Recurrence in Uktra Rapid Opiate Detoxification in Opiate and Heroin Dependents.</article-title><source>J Guilan Univ Med Sci.</source><year>2008</year><volume>17</volume><issue>67</issue><fpage>55</fpage><lpage>64</lpage></element-citation></ref><ref id="A24421R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogue</surname><given-names>A</given-names></name><name><surname>Dauber</surname><given-names>S</given-names></name><name><surname>Henderson</surname><given-names>CE</given-names></name><name><surname>Bobek</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Lichvar</surname><given-names>E</given-names></name><etal>et al.</etal></person-group><article-title>Randomized Trial of Family Therapy Versus Nonfamily Treatment for Adolescent Behavior Problems in Usual Care.</article-title><source>J Clin Child Adolesc Psychol.</source><year>2015</year><volume>44</volume><issue>6</issue><fpage>954</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1080/15374416.2014.963857</pub-id><pub-id pub-id-type="pmid">25496283</pub-id></element-citation></ref><ref id="A24421R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habibi</surname><given-names>R</given-names></name><name><surname>Karshky</surname><given-names>H</given-names></name><name><surname>Dashtgard</surname><given-names>A</given-names></name><name><surname>Heidary</surname><given-names>A</given-names></name><name><surname>Talaei</surname><given-names>A</given-names></name></person-group><article-title>[Validity The Reliability of The Bramson's Quit Addiction Self Efficacy Questionnaire].</article-title><source>Hakim.</source><year>2012</year><volume>15</volume><issue>1</issue><fpage>53</fpage><lpage>9</lpage></element-citation></ref><ref id="A24421R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>LH</given-names></name></person-group><article-title>The Reliability and Validity of the Coopersmith Self esteem Inventory-Form B.</article-title><source>Educational and Psychological Measurement.</source><year>1985</year><volume>45</volume><issue>4</issue><fpage>945</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/0013164485454027</pub-id></element-citation></ref><ref id="A24421R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BW</given-names></name><name><surname>Redfield</surname><given-names>DL</given-names></name><name><surname>Miller</surname><given-names>RL</given-names></name><name><surname>Simpson</surname><given-names>RE</given-names></name></person-group><article-title>The Coopersmith Self esteem Inventory: A Construct Validation Study.</article-title><source>Educational and Psychological Measurement.</source><year>1983</year><volume>43</volume><issue>3</issue><fpage>907</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1177/001316448304300332</pub-id></element-citation></ref><ref id="A24421R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myhill</surname><given-names>J</given-names></name><name><surname>Lorr</surname><given-names>M</given-names></name></person-group><article-title>The coopersmith self esteem inventory: Analysis and partial validation of a modified adult form.</article-title><source>Journal of Clinical Psychology.</source><year>1978</year><volume>34</volume><issue>1</issue><fpage>72</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/1097-4679(197801)34:1&#x0003c;72::AID-JCLP2270340115&#x0003e;3.0.CO;2-T</pub-id><pub-id pub-id-type="pmid">641187</pub-id></element-citation></ref><ref id="A24421R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>KE</given-names></name><name><surname>Sigmon</surname><given-names>SC</given-names></name><name><surname>Strain</surname><given-names>EC</given-names></name><name><surname>Heil</surname><given-names>SH</given-names></name><name><surname>Higgins</surname><given-names>ST</given-names></name></person-group><article-title>The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.</article-title><source>Drug Alcohol Depend.</source><year>2011</year><volume>119</volume><issue>1-2</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2011.05.033</pub-id><pub-id pub-id-type="pmid">21741781</pub-id></element-citation></ref><ref id="A24421R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RJ</given-names></name><name><surname>Aston-Jones</surname><given-names>G</given-names></name></person-group><article-title>Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence.</article-title><source>Brain Struct Funct.</source><year>2008</year><volume>213</volume><issue>1-2</issue><fpage>43</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1007/s00429-008-0191-3</pub-id><pub-id pub-id-type="pmid">18651175</pub-id></element-citation></ref><ref id="A24421R31"><label>31</label><element-citation publication-type="report"><person-group person-group-type="author"><collab>U.S. Department of State.</collab></person-group><source>International Narcotics Control Strategy Report;</source><year>2011.</year></element-citation></ref><ref id="A24421R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kresina</surname><given-names>TF</given-names></name><name><surname>Bruce</surname><given-names>RD</given-names></name><name><surname>Pirard</surname><given-names>S</given-names></name><name><surname>Mulvey</surname><given-names>K</given-names></name><name><surname>Huesca</surname><given-names>RS</given-names></name></person-group><article-title>International Expansion of the Use of Pharmacotherapies for the Treatment of Opioid Dependence.</article-title><source>Clin Exp Pharmacol.</source><year>2012</year><fpage>S5</fpage><lpage>01</lpage></element-citation></ref><ref id="A24421R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirinbayan</surname><given-names>P</given-names></name><name><surname>Rafiey</surname><given-names>H</given-names></name><name><surname>Vejdani Roshan</surname><given-names>A</given-names></name><name><surname>Narenjiha</surname><given-names>H</given-names></name><name><surname>Farhoudian</surname><given-names>A</given-names></name></person-group><source>Alcohol and Alcoholism.</source><year>2010</year><volume>5</volume><issue>suppl 1</issue><fpage>3231</fpage><lpage>6</lpage></element-citation></ref><ref id="A24421R34"><label>34</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Marlatt</surname><given-names>GA</given-names></name><name><surname>Donovan</surname><given-names>DM</given-names></name></person-group><source>Relapse Prevention, Second Edition: Maintenance Strategies in the Treatment of Addictive Behaviors.</source><year>2005</year><publisher-name>Guilford Publications</publisher-name><isbn>9781606238318</isbn></element-citation></ref><ref id="A24421R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname><given-names>E</given-names></name><name><surname>Augustyn</surname><given-names>M</given-names></name><name><surname>Fitzgerald</surname><given-names>E</given-names></name><name><surname>Sandler</surname><given-names>J</given-names></name><name><surname>Ferreira-Cesar Suarez</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><etal>et al.</etal></person-group><article-title>Improving maternal mental health after a child's diagnosis of autism spectrum disorder: results from a randomized clinical trial.</article-title><source>JAMA Pediatr.</source><year>2014</year><volume>168</volume><issue>1</issue><fpage>40</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2013.3445</pub-id><pub-id pub-id-type="pmid">24217336</pub-id></element-citation></ref><ref id="A24421R36"><label>36</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>SJ</given-names></name><name><surname>Snyder</surname><given-names>CR</given-names></name></person-group><source>The Oxford Handbook of Positive Psychology.</source><year>2011</year><publisher-name>OUP USA</publisher-name><isbn>9780199862160</isbn></element-citation></ref><ref id="A24421R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>KJ</given-names></name><name><surname>McCrady</surname><given-names>BS</given-names></name><name><surname>Abrams</surname><given-names>DB</given-names></name><name><surname>Labouvie</surname><given-names>EW</given-names></name></person-group><article-title>Taking an individualized approach to the assessment of self efficacy and the prediction of alcoholic relapse.</article-title><source>Journal of Psychopathology and Behavioral Assessment.</source><year>1994</year><volume>16</volume><issue>2</issue><fpage>111</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/BF02232722</pub-id></element-citation></ref><ref id="A24421R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pashaei</surname><given-names>T</given-names></name><name><surname>Shojaeizadeh</surname><given-names>D</given-names></name><name><surname>Rahimi Foroushani</surname><given-names>A</given-names></name><name><surname>Ghazitabatabae</surname><given-names>M</given-names></name><name><surname>Moeeni</surname><given-names>M</given-names></name><name><surname>Rajati</surname><given-names>F</given-names></name><etal>et al.</etal></person-group><article-title>Effectiveness of Relapse Prevention Cognitive-Behavioral Model in Opioid-Dependent Patients Participating in the Methadone Maintenance Treatment in Iran.</article-title><source>Iran J Public Health.</source><year>2013</year><volume>42</volume><issue>8</issue><fpage>896</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">26056645</pub-id></element-citation></ref></ref-list></back></article>